1887

Abstract

Clinical isolates of and collected from 20 Japanese medical facilities between 2000 and 2010 were analysed to evaluate the mechanisms of resistance and antibacterial susceptibilities to 14 antimicrobials. Overall, eight of 484 (1.6 %) and 19 of 359 (5.3 %) were determined to be extended-spectrum β-lactamase (ESBL) phenotype isolates, and the identified ESBLs amongst the isolates were CTX-M-2, -3, -14 and -15, and SHV-12. In contrast, overproduction of chromosomal β-lactamase OXY-2, which was due to a distinct mutation at the − 10 promoter region of this gene, conferred the ESBL phenotype to all the isolates except one. Based on the Clinical and Laboratory Standards Institute breakpoints, all the ESBL phenotype were susceptible to doripenem, flomoxef, moxalactam (latamoxef), cefmetazole and tazobactam/piperacillin, whereas the ESBL phenotype were susceptible to ceftazidime and ceftibuten in addition to the above, with the exception of tazobactam/piperacillin. Amongst the oral antimicrobials, ceftibuten was relatively effective against both ESBL phenotype species compared with levofloxacin and amoxicillin/clavulanic acid.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000057
2015-05-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/5/538.html?itemId=/content/journal/jmm/10.1099/jmm.0.000057&mimeType=html&fmt=ahah

References

  1. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013; Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 57:3012–3020 doi: 10.1128/AAC.02252-12 [CrossRef]
    [Google Scholar]
  2. Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, Shimono N, Akashi K. 2013; Community spread of extended-spectrum β-lactamase-producing Escherichia coli Klebsiella pneumoniae Proteus mirabilis: a long-term study in Japan. J Med Microbiol 62:1038–1043 doi: 10.1099/jmm.0.059279-0 [CrossRef]
    [Google Scholar]
  3. CLSI 2012 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow Aerobically Approved Standard , 9th edn. CLSI Document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  4. CLSI 2013 Performance Standards for Antimicrobial Susceptibility Testing 23rd Informational Supplement M100-S23 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  5. Fournier B, Lagrange PH, Philippon A. 1996; β-Lactamase gene promoters of 71 clinical strains of Klebsiella oxytoca . Antimicrob Agents Chemother 40:460–463
    [Google Scholar]
  6. Fournier B, Gravel A, Hooper DC, Roy PH. 1999; Strength and regulation of the different promoters for chromosomal β-lactamases of Klebsiella oxytoca . Antimicrob Agents Chemother 43:850–855 [CrossRef]
    [Google Scholar]
  7. Hawkey PM. 2008; Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect 14:(Suppl. 1)159–165 doi: 10.1111/j.1469-0691.2007.01855.x [CrossRef]
    [Google Scholar]
  8. Livermore DM. 1995; β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584
    [Google Scholar]
  9. Livermore DM. 2012; Current epidemiology and growing resistance of Gram-negative pathogens. Korean J Intern Med 27:128–142 doi: 10.3904/kjim.2012.27.2.128 [CrossRef]
    [Google Scholar]
  10. Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ. 2013; Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008–2010. Surg Infect (Larchmt) 14:203–208 doi: 10.1089/sur.2012.034 [CrossRef]
    [Google Scholar]
  11. Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Miyamoto Y, Higuchi T, Ono T, Nishio H, Sueyoshi N, other authors. 2012; Epidemiology of Escherichia coli, Klebsiella species, and Proteus mirabilis strains producing extended-spectrum β-lactamases from clinical samples in the Kinki Region of Japan. Am J Clin Pathol 137:620–626 doi: 10.1309/AJCP48PDVKWQOXEZ [CrossRef]
    [Google Scholar]
  12. Pitout JD. 2010; Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70:313–333 doi: 10.2165/11533040-000000000-00000 [CrossRef]
    [Google Scholar]
  13. Rodríguez-Martínez JM, Poirel L, Nordmann P, Fankhauser C, Francois P, Schrenzel J. 2008; Ceftazidime-resistant Klebsiella oxytoca producing an OXY-2-type variant from Switzerland. Int J Antimicrob Agents 32:278–279 doi: 10.1016/j.ijantimicag.2008.04.002 [CrossRef]
    [Google Scholar]
  14. Yano H, Uemura M, Endo S, Kanamori H, Inomata S, Kakuta R, Ichimura S, Ogawa M, Shimojima M, other authors. 2013; Molecular characteristics of extended-spectrum β-lactamases in clinical isolates from Escherichia coli at a Japanese tertiary hospital. PLoS One 8:e64359 doi: 10.1371/journal.pone.0064359 [CrossRef]
    [Google Scholar]
  15. Zhang Y, Zhou H, Shen XQ, Shen P, Yu YS, Li LJ. 2008; Plasmid-borne armA methylase gene, together with bla CTX-M-15 bla TEM-1, in a Klebsiella oxytoca isolate from China. J Med Microbiol 57:1273–1276 doi: 10.1099/jmm.0.2008/001271-0 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000057
Loading
/content/journal/jmm/10.1099/jmm.0.000057
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error